Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportMolecular Targeting Probes Track

Targeting Translocator Protein (TSPO) with GE-180: Imaging brain inflammation and reactive gliosis

Kiel Neumann, J. Huie, Jason Talbott, Sergio Wong, Susanna Rosi, Jacqueline Bresnahan, Michael Beattie and Henry VanBrocklin
Journal of Nuclear Medicine May 2016, 57 (supplement 2) 1032;
Kiel Neumann
1Radiology and Biomedical Imaging University of California San Francisco San Francisco CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Huie
2UCSF Brain and Spinal Injury Center University of California San Francisco San Francisco CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jason Talbott
1Radiology and Biomedical Imaging University of California San Francisco San Francisco CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sergio Wong
1Radiology and Biomedical Imaging University of California San Francisco San Francisco CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susanna Rosi
2UCSF Brain and Spinal Injury Center University of California San Francisco San Francisco CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacqueline Bresnahan
2UCSF Brain and Spinal Injury Center University of California San Francisco San Francisco CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Beattie
2UCSF Brain and Spinal Injury Center University of California San Francisco San Francisco CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henry VanBrocklin
1Radiology and Biomedical Imaging University of California San Francisco San Francisco CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

1032

Objectives Traumatic brain injury (TBI) is an increasingly prevalent health issue and one of the leading causes of morbidity and mortality worldwide. In the US alone over 2.5 million TBIs were reported in 2010 (CDC.gov). Neuroinflammation is an important pathological response to brain injury with associated glial cell activation. Translocator protein (TSPO) levels have been shown to increase in the CNS in response to neuronal damage and inflammation. Several TSPO PET tracers, including archetype [11C](R)-PK11195, [11C]PBR28 and [18F]DPA-714, among others, have highlighted neuroinflammation and reactive gloss associated with traumatic brain injury. The objective of the present study was to demonstrate [18F]GE-180 ( (4S)-N,N-diethyl-9-(2-fluoroethyl)-5-methoxy-2,3,4,4a,9,9a-hexahydro-1H-carbazole-4-carboxamide; Wadsworth et al., Bioorg Med Chem Lett, 2011), uptake in response to TSPO expression following an experimentally induced focal contusion.

Methods [18F]GE-180 was prepared in a single step from the corresponding mesylate precursor. The tracer was purified by HPLC, concentrated on a C18 SepPak® and formulated in 5% ethanol/saline for injection. Male Long-Evans rats were anesthetized and a 6 mm craniectomy was produced in the skull (Sham). A controlled cortical impact was produced using a Leica ImpactOne device to induce traumatic brain injury (TBI). Rats were injected with 150-250 μCi of [18F]GE-180 and imaged 45-75 minutes post-injection using a Siemens InVeon microPET/CT. Control , sham and TBI rats (n=3) were evaluated at 1, 7 and 31 days post injury. Small animal 7T MR was performed to confirm the injury.

Results [18F]GE-180 was prepared in ~25% radiochemical yield (NDC), with >99% radiochemical and >95% chemical purity and specific activity of 400-800 Ci/mmol. [18F]GE-180 synthesis has been automated on two commercial systems. There was no CNS accumulation of [18F]GE-180 in the control or sham animals at all time points. There was a small amount of uptake in the inflamed scar tissue near the craniectomy site in the sham and TBI rats. Uptake and retention of [18F]GE-180 was clearly visible in the MRI confirmed rat TBI at day 7 and day 31 after injury.

Conclusions [18F]GE-180 accumulates in rat brain tissue following traumatic injury to the site corroborating an earlier report with [18F]DPA-714 in a similar model (Wang et al., EJNMMI 2014). This study demonstrates the potential of [18F]GE-180 as a sensitive imaging agent for TBI and response to therapeutic intervention.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 57, Issue supplement 2
May 1, 2016
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Targeting Translocator Protein (TSPO) with GE-180: Imaging brain inflammation and reactive gliosis
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Targeting Translocator Protein (TSPO) with GE-180: Imaging brain inflammation and reactive gliosis
Kiel Neumann, J. Huie, Jason Talbott, Sergio Wong, Susanna Rosi, Jacqueline Bresnahan, Michael Beattie, Henry VanBrocklin
Journal of Nuclear Medicine May 2016, 57 (supplement 2) 1032;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Targeting Translocator Protein (TSPO) with GE-180: Imaging brain inflammation and reactive gliosis
Kiel Neumann, J. Huie, Jason Talbott, Sergio Wong, Susanna Rosi, Jacqueline Bresnahan, Michael Beattie, Henry VanBrocklin
Journal of Nuclear Medicine May 2016, 57 (supplement 2) 1032;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Molecular Targeting Probes Track

  • Synthesis and preliminary biological evaluation of a novel P2X7R radioligand [18F]IUR-1601
  • In vivo evaluation of [225Ac]Ac-DOTAZOL for α-therapy of bone metastases
  • Case study: Evaluating the new University of Florida hybrid pediatric phantoms and tissue weighting factors from ICRP Publication 103 for diagnostic dosimetry
Show more Molecular Targeting Probes Track

SPECIAL MTA: Preclinical Probes for Neuroimaging Posters

  • Discovery of a novel radioligand [11C] AS2471907 for PET imaging of the brain 11β-HSD1
  • Imaging glucose brain metabolism changes in SIV chronically-infected macaques upon starting or stopping antiretroviral therapies
  • Novel Tau-SPECT Tracers Based on Benzoimidazopyridine for Imaging Tau Aggregates in Alzheimer’s Disease
Show more SPECIAL MTA: Preclinical Probes for Neuroimaging Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire